Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Stephen Falk"'
Autor:
Janet Graham, Mahesh K. B. Parmar, Emma Yates, Tim Maughan, Jenny F. Seligmann, Louise Brown, David Fisher, Kai-Keen Shiu, Fiona Collinson, Ewan Brown, Philip Quirke, Stephen Falk, Richard H. Wilson, Susan D. Richman, Gary Middleton, Harpreet Wasan, Richard Kaplan, Richard Adams, Rachel Butler, Matthew T. Seymour, Leslie Samuel
Publikováno v:
Journal of Clinical Oncology. 39:3693-3704
PURPOSE Despite extensive randomized evidence supporting the use of treatment breaks in metastatic colorectal cancer (mCRC), they are not universally offered to patients despite improvements in quality of life without detriment to overall survival (O
Autor:
Simon Gollins, Rajarshi Roy, Maria A. Hawkins, Gareth Griffiths, Tim Maughan, Lisette Sheena Nixon, Chris Nicholas Hurt, Ruby Ray, Stephen Falk, Andrew Bateman, Tom Crosby, Sarah Gwynne, Ricky A. Sharma, Somnath Mukherjee, Catrin Cox, Ganesh Radhakrishna, David Sebag-Montefiore, Joanne Canham, Heike I. Grabsch, Nick Maynard
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 153, 153-161. ELSEVIER SCI LTD
European Journal of Cancer, 153, 153-161. ELSEVIER SCI LTD
Aim This is the first randomised study to evaluate toxicity and survival outcomes of two neoadjuvant chemoradiotherapy (CRT) regimens for patients with localised oesophageal adenocarcinoma (OAC) or gastro-oesophageal junction (GOJ) adenocarcinoma. Th
Autor:
Robin M. Rudd, Richard Jones, Alex Edwards, Siow Ming Lee, Matthew Hatton, Allan Hackshaw, Geraldine Skailes, Elizabeth Toy, Yenting Ngai, Sunil Upadhyay, Penella J. Woll, Stephen Falk, Rohit Lal, Conrad R. Lewanski
Publikováno v:
European Journal of Cancer
Purpose We previously demonstrated that the median survival of patients with poor prognosis non–small cell lung cancer (NSCLC) considered unfit for first-line platinum chemotherapy was
Highlights • 83% advanced NSCLC patients unfit for chemo
Highlights • 83% advanced NSCLC patients unfit for chemo
Autor:
John Bridgewater, Stephen Falk, Kinnari Patel, Alan Anthoney, Harpreet Wasan, W David J Ryder, Safia Barber, Juan W. Valle, Daniel H. Palmer, Yuk Ting Ma, Roopinder Gillmore, Arvind Arora, Jonathan Wadsley, John Ramage, Angela Lamarca, Claire Hobbs, Timothy Iveson, Justin S. Waters, Linda Davies, Paul Ross, Anthony Maraveyas
Publikováno v:
The Lancet Oncology. 22:e288-e289
Autor:
Marjorie Tomlinson, Juan W. Valle, Meg Finch-Jones, O. James Garden, S Pugh, Tamas Hickish, Joanne Hornbuckle, Sharadah Essapen, Raaj K. Praseedom, Chan Ton, Marcia Hall, Alison Brewster, Sarah Smith, A Mayer, Nariman Karanjia, Stephen Falk, Nagappan Kumar, Mark A. Hill, Stephen Fenwick, Tim Maughan, John Bridgewater, Alison Brown, Sherif Raouf, Andrea Corkhill, Amy Whitehead, Vanessa Potter, Charlotte Rees, Tom Diamond, Ajith K. Siriwardena, David J. Smith, Susan Cleator, Charles Wilson, Sarah Slater, John N. Primrose, David Cunningham, Gareth Griffiths, Hassan Malik, Nasim Ali, Alex Allen, Christopher Baughan, Satya Bhattacharya, Timothy Iveson, Charles Lowdell, Satvinder Mudan, Brian R. Davidson, Louise Stanton, Paul Ross, Luke Nolan, Iain Cameron, Ann O'Callaghan, Robert J. Thomas, Ewan Brown, Tom Maishman, Anne Moody, Sally Clive, Clare Barlow, Mike Radford, Nua Chan Ton, Georgina Walker, David Tsang, Derek A. O'Reilly, Alaaeldin Shablack, Colin Purcell, Mark Peterson, Zina Eminton, Myrddin Rees, Nigel Heaton, Jane Mellor
Publikováno v:
New EPOC investigators 2020, ' Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC) : long-term results of a multicentre, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 21, no. 3, pp. 398-411 . https://doi.org/10.1016/S1470-2045(19)30798-3
The Lancet. Oncology
The Lancet. Oncology
Background: The interim analysis of the multicentre New EPOC trial in patients with resectable colorectal liver metastasis showed a significant reduction in progression-free survival in patients allocated to cetuximab plus chemotherapy compared with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1626d37868998ab4d8cd96edfc217e80
https://doi.org/10.1016/S1470-2045(19)30798-3
https://doi.org/10.1016/S1470-2045(19)30798-3
Autor:
Mark R. Middleton, P S Virdee, Leena Elhussein, Martin Eatock, M Goff, Sharon Love, Anne Thomas, Stephen Falk, Joanna Moschandreas, Richard C. Turkington, D. Alan Anthoney, L Collins, Simon Lord
Publikováno v:
Thomas, A, Virdee, P S, Eatock, M, Lord, S R, Falk, S, Anthoney, D A, Turkington, R C, Goff, M, Elhussein, L, Collins, L, Love, S, Moschandreas, J & Middleton, M R 2020, ' Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma ', European Journal of Cancer, vol. 124, pp. 131-141 . https://doi.org/10.1016/j.ejca.2019.10.010
European Journal of Cancer
European Journal of Cancer
Background AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently assess safety/preliminary cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f3f4d7b04b1b1073ec0ebfa84b2946
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
Autor:
Mohammed Abdul Imran Khan, Tania Tillett, Rajarshi Roy, Simon Lord, Zuzana Stokes, Helen Howard, Matthew T. Seymour, Christine Allmark, C. Handforth, Guptal Kamalnayan, Jonathan Nicoll, Eszter Katona, Joseph Mano, Sharon Ruddock, Nick Maisey, David A Cairns, Galina Velikova, Ángel David Roncancio García, Jonathan Wadsley, Anirban Chatterjee, Peter Hall, Daniel Swinson, Stephen Falk, Pei Loo Ow, Helen Marshall, Simon Grumett, Sebastian Cummins, Heike I. Grabsch, Jo Dent, Kamposioras Kostantinos-Vellios, Justin Waters, Russell D. Petty, Anne Crossley, Thomas K. Waddell
Publikováno v:
SSRN Electronic Journal.
Background: GO2 sought to optimise chemotherapy dosing in older/frail patients with advanced gastroesophageal cancer, and explored baseline geriatric assessment (GA) as a tool for treatment decision-making. Methods: Patients were recruited for whom f
Autor:
Pei Loo Ow, Angel Garcia, Lesley Samuel, Rajarshi Roy, Adam McGeoch, D. Fyfe, W Saku, Simon Aird Grumett, Jonathan Nicoll, Jo Dent, Tom Samuel Waddell, Jo Webster, Christine Allmark, Tania Tillett, Colin Askill, Justin S. Waters, C. Handforth, Erica Beaumont, Vallipuram Vigneswaran, Sharon Ruddock, Nick Wadd, Syed Zubair, Kinnari Patel, Vanessa Potter, Daniel Propper, Olwyn Williams, Marc Jones, Kamalnayan Guptal, Peter Hall, Gareth Griffiths, Joseph Mano, Juan W. Valle, Sheela Rao, David A Cairns, Go Trial Investigators, Eszter Katona, Nick Maisey, Chris Twelves, Daniel Swinson, Nicholas Reed, Heike I. Grabsch, Joanne Askey, Jonathan Wadsley, Tom Roques, Sue Cheeseman, Stephen Falk, Louise Medley, Arshad Jamil, Emma Cattell, Victori Kunene, Matthew R. Sydes, Charles Candish, Claire Hobbs, Rebecca Herbertson, Jo Parkinson, Nicholas S. Reed, Louise Brook, Zuzana Stokes, Mohammed Khan, Ann Crossley, Elin Jones, George Bozas, Sebastian Cummins, Anirban Chatterjee, Michael Bennet, Helen Marshall, Pavel Bezecny, David Sherriff, Matthew T. Seymour, Lauren Gorf, Galina Velikova, Jean Gall, Kamposioras Konstantinos-Velios, Sally Clive, Eleanor James, Fiona Collinson, Dunca Wilkins, Simon Lord, Julia Brown, Serena Hilman, A. Robinson, Richard Ellis, Alaaeldin Shablak, Russell D Petty, Sherif Raouf, Helen Howard
Publikováno v:
Hall, P S, Swinson, D, A. Cairns, D, S. Waters, J, Petty, R, Allmark, C, Ruddock, S, Falk, S, Wadsley, J, Roy, R, Tillett, T, Nicoll, J, Cummins, S, Mano, J, Grumett, S, Stokes, Z, Konstantinos-Velios, K, Chatterjee, A, Garcia, A, Waddell, T, Guptal, K, Maisey, N, Khan, M, Dent, J, Lord, S, Crossley, A, Katona, E, Marshall, H, I. Grabsch, H, Velikova, G, Loo Ow, P, Handforth, C, Howard, H & T. Seymour, M 2021, ' Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal CancerThe GO2 Phase 3 Randomized Clinical Trial ', JAMA Oncology . https://doi.org/10.1001/jamaoncol.2021.0848
JAMA Oncology, 7(6), 869-877. American Medical Association
JAMA Oncology, 7(6), 869-877. American Medical Association
Importance: Older and/or frail patients are underrepresented in landmark cancer trials. Tailored research is needed to address this evidence gap. Objective: The GO2 randomized clinical trial sought to optimize chemotherapy dosing in older and/or frai
Autor:
Susan D. Richman, Jenny F. Seligmann, Philip Quirke, Tim Maughan, Focus Investigators, Emma Yates, Richard Kaplan, Rachel Butler, Ewan Brown, Matthew T. Seymour, Richard H. Wilson, Louise Brown, Richard Adams, David Fisher, Stephen Falk, Janet Graham, Fiona Collinson
Publikováno v:
Journal of Clinical Oncology. 39:3504-3504
3504 Background: There is extensive randomised evidence supporting the use of treatment breaks in mCRC, but breaks from treatment are not universally offered to patients despite reductions in toxicity, without detriment to OS. Prior trials have shown
Autor:
Stephen Falk, Susan J Dutton, Wasat Mansoor, David A J Stevenson, Caroline Clark, Russell D. Petty, Aileen Osborne, Asa Dahle-Smith, Angel Garcia-Alonso, Mark Harrison, Joyce Thompson, Graeme I. Murray, Ian Chau, Irene Chong, Jonathan Wadsley, Corran Roberts, Doreen Massie, Zosia Miedzybrodzka, Anirban Chatterjee, Sean Elyan, David Walter Fyfe, David Ferry
Publikováno v:
Journal of Clinical Oncology. 35:2279-2287
Purpose The Cancer Esophagus Gefitinib trial demonstrated improved progression-free survival with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib relative to placebo in patients with advanced esophageal cancer who had